Seven Eight Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Seven Eight Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,824	Closed	-$1.67M	–	703
2024 Q1	$1.67M	Buy	4,824 +1,972	+69%	+$648K	0.17%	176
2023 Q4	$921K	Buy	2,852 +675	+31%	+$212K	0.11%	277
2023 Q3	$780K	Buy	+2,177	New	+$840K	0.09%	301
2022 Q2	–	Sell	-1,081	Closed	-$609K	–	394
2022 Q1	$609K	Buy	+1,081	New	+$652K	0.08%	288
2019 Q2	–	Sell	-2,459	Closed	-$752K	–	582
2019 Q1	$752K	Buy	+2,459	New	+$664K	0.04%	396
2017 Q4	–	Sell	-2,500	Closed	-$556K	–	455
2017 Q3	$556K	Buy	2,500 +2,300	+1,150%	+$518K	0.07%	330
2017 Q2	$45K	Sell	200 -6,800	-97%	-$1.48M	0.01%	489
2017 Q1	$1.4M	Buy	7,000 +5,500	+367%	+$1.06M	0.27%	132
2016 Q4	$273K	Buy	+1,500	New	+$256K	0.05%	369

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Seven Eight Capital's BIO Position: Q2 2024 in Review

Seven Eight Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 4,824 shares — an estimated $1.67M sold.

Seven Eight Capital first reported a position in BIO in Q4 2016 and held it in 9 quarters. The position peaked at $1.67M in Q1 2024. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Seven Eight Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Seven Eight Capital sold 4,824 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $1.67M.
Seven Eight Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and held it in 9 quarters.
Seven Eight Capital's Bio-Rad Laboratories Class A position peaked at $1.67M in Q1 2024.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.